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Establishing a higher priority for chronic kidney disease in Peru
In keeping with eﬀ orts to expand universal health care 
(UHC) throughout the Americas, Peru established a UHC 
programme in 2009. Although it was a tremendous 
achievement, Peru must continue to address non-
communicable chronic diseases in upcoming 
health-care reforms. For instance, the 2009 reforms 
established a fund to support high-cost therapies for 
certain chronic conditions; however, the coverage is not 
universal throughout the country and essential services 
for other chronic conditions remain uncovered. 
Within the set of chronic diseases being targeted by 
the reforms, chronic kidney disease presents a large 
burden in view of its insidious progression, long-
term complications, and complex comorbidities, 
including hypertension and diabetes.1 Indeed, chronic 
kidney disease is one of the highest causes of Peruvian 
mortality.2 Its prevalence in some regions is about 
16·8%1—a stark contrast to the 1% prevalence estimated 
for Lima in 1990.3 Moreover, end-stage renal disease is 
expensive to manage, costing US$30 000–50 000 per 
patient per year,4 which represents roughly ten times the 
annual minimum-wage income in Peru.5 
When implemented during the early stages of 
chronic kidney disease, the costs of preventive care are 
minimal. A cost-beneﬁ t analysis including hypertensive 
Peruvians at risk of chronic kidney disease estimated the 
total cost savings from preventive interventions to be 
$188 518 645 over 5 years if dialysis is avoided.6 Focus on 
prevention of both primary and secondary chronic kidney 
disease will save lives in a health-care system not prepared 
to manage renal disease in later, more expensive stages.
As a Group 2 UHC country, ie, having made substantial 
progress towards UHC but still facing signiﬁ cant 
coverage gaps, Peru has UHC programmes and systems 
in place and has increased the proportion of Peruvians 
with insurance to 70·1% of the total population.7 
The introduction of Seguro Integral de Salud (SIS), a 
programme of the Ministry of Health targeting poor 
and the extremely poor groups, and the natural growth 
in EsSalud, Peru’s social security scheme that provides 
formal insurance to employees and their beneﬁ ciaries, 
have resulted in an expansion of insurance coverage.7 
However, SIS, which covers more Peruvians, does not 
support the management of chronic kidney disease. In 
2012, the Intangible Health Solidarity Fund (FISSAL), a 
division within SIS tasked to manage funding for certain 
high-cost chronic diseases, expanded the treatment for 
end-stage renal disease to include a select group of low-
income Peruvians.7 Yet FISSAL provides no clear guidelines 
governing the distribution of funds to poor people and, 
aside from haemodialysis, no comprehensive count of 
recipients of renal replacement therapy covered by FISSAL 
is available to inform policy makers. For instance, in 
2014, FISSAL provided haemodialysis to 1983 Peruvians; 
however, the number of FISSAL peritoneal dialysis and 
transplant recipients is unknown and expected to be 
much lower given that these later services are only 
provided within a limited number of hospitals.8
Peru’s current national health survey, which is 
based on the Demographic and Health Survey with a 
sampling frame focusing on women of reproductive 
age,7 together with previous experience using STEPS, 
a WHO surveillance programme, could help build a 
comprehensive national health surveillance system 
to monitor chronic diseases on a population level. 
Comprehensive surveillance would aid detection, 
awareness, referral, and tracking of chronic kidney 
disease.9 Surveillance could parallel the chronic kidney 
disease detection system from the US Centers for 
Disease Control and Prevention and include centralised 
reporting of estimated glomerular ﬁ ltration rate 
after serum creatinine measurements from sentinel 
laboratories, which captures moderate and severe 
chronic kidney disease stages.9 Comprehensive 
surveillance would also permit impact assessment 
throughout Peru’s health-care reform.
Latin American countries with the highest rate of renal 
replacement therapy (RRT) are those with UHC inclusive 
of at least one form of RRT, ie, haemodialysis, peritoneal 
dialysis, or transplantation (appendix). For example, 
the Chilean UHC system created a mixed private–public 
network that exceeded the demand for and lowered the 
cost of haemodialysis, and established a universal organ 
donation policy.10 Also, Costa Rica’s 98% insurance rate, 
which includes universal renal replacement therapy and 
a high rate of living kidney donations, have contributed 
to the country’s leadership in kidney transplantation.11
Fragmentation of communication and structure within 
and between Peruvian providers of information requires 
uniﬁ cation for insurers and providers to work optimally.8 
See Online for appendix
For the WHO surveillance 
programme see http://www.
who.int/chp/steps/en
For more on the CDC chronic 
disease detection system see 
http://nccd.cdc.gov/ckd
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Working alongside nations with established UHC 
programmes, which include universal access to at least 
one form of renal replacement therapy, might provide 
insight to eﬃ  cacious practices that Peru could adopt. 
This partnership could parallel the current kidney health 
cooperation project between Uruguay and Bolivia.12
Although universal coverage of renal replacement 
therapy will address the problem of access, it will not 
address the rising prevalence of chronic kidney disease1–3 
and its ensuing economic strain. For instance, Taiwan’s 
highly regarded National Health Insurance programme 
increased demand for end-stage renal disease care; 
however, since 2006, Taiwan’s prevalence of end-stage 
renal disease remains one of the highest globally.13 This 
trend emphasises the need for insurance expansion 
concomitant with strengthening of the health-care 
system focused on primary and secondary prevention.  
Prioritising prevention and treatment of chronic 
kidney disease in future UHC reforms would allow Peru 
to mitigate ﬁ nancial hardship associated with end-stage 
renal disease therapy and address prominent comorbid 
diseases.
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